Palisade Capital Management LP Invests $5.79 Million in Thermo Fisher Scientific Inc. $TMO

Palisade Capital Management LP bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 11,558 shares of the medical research company’s stock, valued at approximately $5,795,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Elyxium Wealth LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.9% during the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock worth $613,000 after buying an additional 20 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. lifted its position in shares of Thermo Fisher Scientific by 0.7% during the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after acquiring an additional 20 shares during the period. Canandaigua National Trust Co of Florida boosted its stake in Thermo Fisher Scientific by 3.0% during the fourth quarter. Canandaigua National Trust Co of Florida now owns 765 shares of the medical research company’s stock worth $443,000 after acquiring an additional 22 shares in the last quarter. Finally, Princeton Capital Management LLC increased its stake in Thermo Fisher Scientific by 2.4% in the fourth quarter. Princeton Capital Management LLC now owns 922 shares of the medical research company’s stock valued at $534,000 after purchasing an additional 22 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $627.96 on Wednesday. The stock has a market cap of $232.19 billion, a price-to-earnings ratio of 33.78, a PEG ratio of 2.56 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $647.00. The firm’s 50-day simple moving average is $548.75 and its 200 day simple moving average is $510.05.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the business posted $4.28 earnings per share. The company’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Royal Bank Of Canada upped their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday, July 24th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Jefferies Financial Group restated a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Finally, Evercore set a $570.00 target price on Thermo Fisher Scientific in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at $13,927,815. The trade was a 1.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 73,493 shares of company stock worth $43,950,381. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.